Current Cancer Trials

The majority of tumors are ignored by the immune system and it was thought for long time that tumor antigens did not exist. However, recently a number of tumor antigens have been described. These antigens reside on cancer cells and can be recognized by specific T-cells which can ultimately attack and destroy the tumor. The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

MannKind has initiated a Phase 1 clinical study for an investigational cancer immunotherapy. This is a multicenter, open label clinical trial of immune response, safety and tolerability of DNA vector pPRA-PSM with synthetic peptides E-PRA and E-PSM in subjects with advanced solid malignancies.

MKC1106-PP is MannKind’s first potential cancer immunotherapy. It is a DNA vector with two synthetic peptides delivered via a plasmid prime-peptide boost treatment. The clinical study is designed to target two tumor-specific antigens, preferential antigen of melanoma (PRAME) and prostate specific membrane antigen (PSMA), on the basis of their level of expression in commonly occurring adult malignancies, such as ovarian, prostate, renal, pancreatic, breast and colon carcinomas as well as in melanoma.

For more information or to enroll, visit www.clinicaltrials.gov